Pain Descriptions May Predict Presence of Neuropathic Pain

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 5 No 10
Volume 5
Issue 10

BUFFALO, NY-Just by looking at the words cancer pain patients used to describe their pain, researchers were able to correctly predict in 66% of cases which patients had neuropathic pain, Dr. Thomas Sist, of the Roswell Park Cancer Institute, said in his poster presentation at the 8th World Congress on Pain.

BUFFALO, NY-Just by looking at the words cancer pain patientsused to describe their pain, researchers were able to correctlypredict in 66% of cases which patients had neuropathic pain, Dr.Thomas Sist, of the Roswell Park Cancer Institute, said in hisposter presentation at the 8th World Congress on Pain.

The study involved a group of patients with cancer or chronicbenign pain seen at the Roswell Park Pain Clinic. According toan independent clinical assessment, 122 had exclusively somaticpain, 41 visceral pain, and 42 neuropathic pain. Patients withmixed pain syndromes were excluded from the study.

When these diagnoses were compared with the patients' answerson the McGill Pain Questionnaire, the researchers found that thepercentage of sensory words chosen to describe the pain was significantlyhigher for the neuropathic pain patients than for those with somaticand visceral pain.

"Patients with neuropathic pain were much more likely touse words like shooting, flashing, pricking, drilling, stabbing,sharp, and cutting-words that describe very distinct short-termphasic kinds of pain," Dr. Sist said.

Also, as would be expected, the neuropathic pain patients oftenused words suggesting a causalgic kind of pain, such as hot, burning,scalding, searing, smarting, and stinging.

"In fact, the hot, burning, scalding, searing words werethe ones that, of all the words listed, most assuredly predictedthe presence of neuropathic pain," he said.

Dr. Sist noted that the findings will be the basis for a largerstudy that will try to relate word selection more precisely toclinical findings, "the goal being to eventually providethe physician with some predictive capability when making paindiagnoses."

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
Specialties including neurosurgery, radiation oncology, and neuro-rehabilitation all play a notable role in the care of patients with brain tumors.
Treatment-related toxicities during neuro-oncology therapy appear well managed with dose modifications and treatment cycle holds.
The phase 3 NIVOSTOP trial evaluated an anti–PD-1 immunotherapy, nivolumab, in a patient population similar in the KEYNOTE-689 trial.
CAR T-cell therapies appear to be an evolving modality in the treatment of those with intracranial tumors, said Sylvia Kurz, MD, PhD.
Opportunities to further reduce relapses include pembrolizumab-based combination therapy and evaluating the agent’s contribution before and after surgery.
For patients with locally advanced head and neck cancers, the current standard of care for curative therapy has a cure rate of less than 50%.
According to Maurie Markman, MD, patient-reported outcomes pertain to more relevant questions surrounding the impact of therapy for patients.
CancerNetwork® spoke with Neha Mehta-Shah, MD, MSCI, about the clinical landscape for patients undergoing treatment for rare lymphomas.
Related Content